Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Joe Krupa who wrote (13509)	6/7/2004 12:17:06 PM
From: Cal Gary	Respond to of 14101

Deja-Vu LOL

To: Joe Krupa who wrote (13509)	6/9/2004 2:51:35 PM
From: Joe Krupa	Read Replies (3) \| Respond to of 14101

Dimethaid announces Annual Meeting date cnw.ca TORONTO, June 9 /CNW/ - Pharmaceutical developer Dimethaid Research Inc. (TSX: DMX) announced today that its board of directors has scheduled the Annual General Meeting of Shareholders for September 21, 2004 to consider annual business, including the matters raised in the requisition received from a dissident group of shareholders on May 19, 2004. The Company has set August 3, 2004 as the record date for the meeting. The Annual General Meeting, to be held in Toronto, Ontario, has been moved up from its originally anticipated late October date. The company has accelerated auditing procedures to accommodate this condensed timeline and avoid the unnecessary cost of two shareholder meetings. About Dimethaid Research Inc. Dimethaid Research Inc. is a publicly traded, Canadian, pharmaceutical company headquartered in Markham, Ontario, with manufacturing facilities in Varennes, Québec and Wanzleben, Germany. The company develops and commercializes targeted therapeutic drugs designed to produce minimal side effects. Dimethaid's two technology platforms focus on immune system regulation and transcellular drug delivery. Products are aimed at expanding treatment options in oncology, immunology, rheumatology and the therapeutic management of chronic viral infections. For more information, please visit www.dimethaid.com. This release may contain forward-looking statements, subject to risks and uncertainties beyond management's control. Actual results could differ materially from those expressed here. Risk factors are discussed in the Company's annual information form filed with the securities commissions in each of the provinces of Canada. The Company undertakes no obligation to revise forward-looking statements in light of future events. %SEDAR: 00002418EF